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Abstract
Testicular cancer (TCa) has a relatively rare incidence and mortality, but has not been thoroughly evaluated. We analyzed global
variations and recent trends in TCa incidence and mortality.
Age-standardized rates (ASRs) of TCa incidence and mortality were retrieved from the GLOBOCAN 2012 database. Temporal
patterns were assessed using data obtained from the Cancer Incidence in Five Continents (volumes I–X) and World Health
Organization Mortality databases. The incidence and mortality trends over the last 10 years were analyzed using join point analysis.
Western and Northern Europe had the highest incidence of TCa (ASR=8.7 and 7.2, respectively), with most countries showing an
increase in incidence rates except for China, which had a stable incidence. Incidence rates were markedly increased in Southern
European countries (average annual percent change of 6.8% in Croatia and 6.1% in Spain) but were attenuated in western Europe.
The highest mortality rates were observed in western Asia (ASR=0.7), with most countries showing a decrease in mortality.
While the incidence of TCa has increased, mortality from TCa has decreased in most countries. More socioeconomically
developed countries had a higher incidence of TCa with lower mortality.
Abbreviations: AAPC = average annual percent change, ASRs = age-standardized rates, Lowess = locally weighted regression,
TCa = testicular cancer.
Keywords: cancer trends, epidemiology, incidence, mortality, testicular cancer1. Introduction
Testicular cancer (TCa) is a relatively rare cancer on a per-
population basis, accounting for 1% to 2% of all neoplasms in
men and boys[1,2] and over 52,000 new cases and almost 10,000
deaths worldwide in 2008.[3] However, TCa is the most common
malignancy in young adult men (aged 15–40 years).[4] The
natural course of TCa is metastasis that eventually results in
death. Although there are no primary methods to prevent TCa at
the present time, multimodal treatments, including surgery,Editor: Giuseppe Lucarelli.
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1chemotherapy, and radiation, have been developed, resulting in a
high curative rate for TCa.
TCa incidence has been increasing over the last 30 to 40
years,[5,6] affecting mainly Caucasian populations. Incidence
rates among young white men in Nordic countries are more than
10 times higher than those observed among black and Asian
men.[6,7] The increase in TCa incidence is mainly driven by birth
cohort effects, meaning that an individual’s risk is largely a
function of the era in which he is born.[8–10] Furthermore, several
studies have noted that immigrants retain their original region’s
incidence of TCa, even after relocating to a different geographical
region.[3,11,12]
Known risk factors for TCa are cryptorchidism, a previous
diagnosis of TCa, a genetic predisposition, andmaternal estrogen
exposure.[13–16] However, we do not clearly understand why
distinct geographic and temporal variations exist in the incidence
of TCa. As TCa incidence and mortality have distinct geographic
variations, withNorthern andWestern Europe having the highest
incidence rates,[8] most epidemiological studies have focused on
European, but not global, cohorts. Previous studies of global TCa
incidence using the GLOBOCAN 2008 database reported the
highest TCa incidence rates inWestern andNorthern Europe (7.8
cases and 6.7 cases per 100,000 man-years, respectively) and the
lowest incidence rates in Asia and Africa (0.7 cases and 0.4 cases
per 100,000 man-years, respectively).[17] This article provides the
most recent overview of global variations in TCa incidence and
mortality rates, with a comprehensive description and compari-
son of recent global TCa trends.
2. Materials and methods
2.1. Data sources
Estimated TCa incidence and mortality rates [International
Classiﬁcation of Diseases 10th revision (ICD-10) diagnosis code
C62] were retrieved from the GLOBOCAN database for 184
[18] [24]
Park et al. Medicine (2018) 97:37 Medicinecountries in 2012. GLOBOCAN provides national estimates
of incidence, mortality, and prevalence from the best available
data sources in each country.[18] More developed regions include
Europe, North America, Australia/NewZealand, and Japan. Less
developed regions include Africa, Asia (excluding Japan), Latin
America, and the Caribbean, Melanesia, Micronesia, and
Polynesia, as deﬁned in GLOBOCAN.[18]
Incidence data were derived from population-based cancer
registries, using the Cancer Incidence in Five Continents (CI5)
database, volumes I–X.[19] CI5, the main source of global cancer
incidence data provided by population-based cancer registries
worldwide, has the highest level of validity, completeness, and
comparability because of its rigorous editorial processes.[20]
Mortality data were extracted from the World Health Organiza-
tion Mortality database.[21] The quality of incidence and
mortality data, in terms of coverage and completeness, is known
to vary greatly by country.[21]2.2. Data analysis
Age-standardized rates (ASRs) for TCa incidence and mortality
were computed by year/period and region/country using the
standard world population.[22] Locally weighted regression
(Lowess) curves were used for the graphically presented
smoothed trend lines.[23] To evaluate incidence and mortality
variations in the rates over time, joinpoint regression analysesTable 1
Estimated incidence and mortality of testicular cancer in 2012 by reg
World region Male population (thousands)
Africa 551,385
Eastern Africa 182,067
Middle Africa 69,644
Northern Africa 106,527
Southern Africa 29,775
Western Africa 163,372
Asia 2,193,088
East Asia 824,745
Southeastern Asia 306,015
South-Central Asia 935,661
Western Asia 126,667
Europe 356,519
Central and Eastern Europe 138,209
Northern Europe 49,921
Southern Europe 75,142
Western Europe 93,247
Central and South America and Caribbean 302,545
Caribbean 20,981
Central America 82,115
South America 199,449
North America 172,234
Oceania 18,952
Australia/New Zealand 13,595
Melanesia 4762
Micronesia 256
Polynesia 339
More developed regions† 605,134
Less developed regions‡ 2,989,588
World 3,594,722
ASR=age-standardized rate per 100,000 individuals, TCa= testicular cancer.
∗
Population size data were retrieved from the Department of Economic and Social Affairs, Population D
† Europe, Northern America, Australia/New Zealand, and Japan.
‡ All regions of Africa, Asia (except Japan), Latin America, and the Caribbean, plus Melanesia, Microne
2were used, which include ﬁtting a series of joined, straight lines
to the ASR trend.[24] Logarithmic transformation of the rates, the
standard error (calculated using a binomial approximation), and
a maximum number of 3 joinpoints were speciﬁed as options in
the analyses. To estimate the magnitude and direction of the most
recent trends, the average annual percent change (AAPC) and the
corresponding 95% conﬁdence intervals for the last available
10 years of incidence and mortality data for each country
were calculated. AAPC is a geometrically weighted average of
various APC values from the regression analyses using joinpoint
trend analysis software, with weights equivalent to the lengths of
each segment during the speciﬁed time intervals.[25]3. Results
3.1. Incidence and mortality according to geographical
location
According to the GLOBOCAN estimates, about 55,300 new TCa
cases and 10,400 TCa-related deaths occurred in 2012 (Table 1).
TCa incidence rates varied more than 44-fold worldwide in 2012.
The highest rates were observed in Western Europe (ASR 8.7 per
100,000), Northern Europe (7.2), and Australia/New Zealand
(6.8), and the lowest rates were observed in Middle Africa (0.2)
(Table 1 and Fig. 1A). The regions with the most prominent
incidence data compared with other regions in the same continention
∗
.
TCa incidence TCa mortality
n ASR n ASR
1529 0.4 864 0.3
409 0.3 250 0.2
97 0.2 64 0.2
570 0.6 290 0.3
161 0.6 71 0.3
292 0.3 189 0.2
15,053 0.7 5849 0.3
4346 0.5 1004 0.1
2571 0.9 1236 0.5
5881 0.6 2813 0.3
2255 1.7 796 0.7
21,548 5.6 1612 0.4
4913 3.2 901 0.5
3635 7.2 119 0.2
4783 5.9 265 0.3
8217 8.7 327 0.3
7197 2.2 1504 0.5
222 1 46 0.2
1951 2.3 511 0.6
5024 2.4 947 0.4
8965 5 484 0.2
974 5 38 0.2
953 6.8 27 0.2
18 0.4 11 0.3
3 0.5 0 0
3 0.8 0 0
32,740 5.2 2209 0.3
22,526 0.7 8142 0.3
55,266 1.5 10,351 0.3
ivision, United Nations (http://esa.un.org/unpd/wpp/Download/Standard/Population). [1]
sia, and Polynesia.
Figure 1. International variations in estimates of national age-standardized incidence (A) and mortality rates (B) of testicular cancer in all age groups. [18]
Park et al. Medicine (2018) 97:37 www.md-journal.comincluded Western Asia (1.7), Western Europe (8.7), and
Australia/New Zealand (6.8) (Table 1 and Fig. 1A). When
compared with the incidence data estimated in 2008,[17] the
sharpest rise was observed in Southern Europe (4.2 in 2008 vs 5.9
in 2012).
The highest mortality rate was observed in Western Asia (0.7),
whereas the lowest rates (0.2) were found for most regions of
Oceania (Table 1 and Fig. 1B).3.2. Age-standardized rates for incidence
The overall incidence trends showed volatile curves, while the
recent 10 years of incidence trends showed persistent increases3in most countries worldwide, except in Japan, Switzerland,
and China, which had stable incidences (Figs. 2 and 3A).
Although AAPCs were lowest or insigniﬁcant in Asian
populations, except for Israel at 3%, signiﬁcant but modest
increases were observed in Oceania andNorth America. Of the 3
Latin America and Caribbean registries contributing data, Costa
Rica showed a signiﬁcant increase in incidence (AAPC of 4.6%)
(Figs. 2 and 3A).
Signiﬁcant increases were observed in most Europeancountries, especially in Southern Europe, with AAPCs of 6.8%
in Croatia and 6.1% in Spain. A stabilization of the incidence was
noted within the last decade in Denmark (AAPC of 0.1%),
Switzerland (AAPC of 0.7%), Malta (AAPC of 2.5%), Japan
Figure 2. Trends in age-standardized (world) incidence and mortality rates of testicular cancer in all age groups. Dots are observed values; solid lines are locally
weighted regression curves (30% of the data were used in smoothing each point). [19,21]
Park et al. Medicine (2018) 97:37 Medicine(AAPC of 0.6%), China (AAPC of -0.3%), the Philippines (AAPC
of 0.5%), and Brazil (AAPC of 2.9%).3.3. Age-standardized rates for mortality
Most countries showed decreased mortality, except in
Croatia and Brazil, which had increasing mortality (AAPCs of
1.7% and 1.8%, respectively) (Figs. 2 and 3B). Most Asian
countries showed signiﬁcant decreases in mortality, especially4China, which had a signiﬁcant decrease in mortality (AAPC
of -6.1%).4. Discussion
This paper comprehensively analyzed the epidemiology of
worldwide TCa incidence and mortality using recent, high-
quality data. Continuous increases in global TCa incidence rates
in most countries were noted. Compared with an incidence in
Figure 2. Continued
Park et al. Medicine (2018) 97:37 www.md-journal.com2008 of 52,322, an incidence of 55,266 was found in 2012, a
slight increase. The mortality rate was 10,351 in 2012 compared
with 9874 in 2008, and the incidence-mortality ratio of 2012 was
18.7%, which is lower than that found in 2008 (18.9%),
suggesting beneﬁcial effects of improvements in both the
diagnosis and treatment of TCa.
Although incidence rates varied greatly by geographical region,
Western Europe, Northern Europe, and Australia/New Zealand
had the highest incidence of TCa, whereas Middle Africa had the
lowest. Although a high incidence was noted in Western and
Northern Europe, the mortality rate was relatively low,
suggesting beneﬁcial effects of a prompt diagnosis followed by
effective multimodal treatment and surveillance. However,
whereas the overall incidence of TCa was low in Africa and
Asia, mortality rates roughly equaled incidence rates, likely
because of the lack of effective tools for diagnosis and
treatment.[26] A previous study reported that in patients with
nonseminomatous germ cell tumors, diagnostic delays were5associated with advanced stage at the time of diagnosis and
reduced 5-year survival.[27]
In addition to the stabilization of TCa incidence in Denmark,
the UK, and Ireland both showed a leveling off of the incidence of
TCa over time. However, an increased TCa incidence was noted
in the UK in 2012. The steepest increase in incidence was ﬁrst
observed in Southern Europe in 2008, and similar trends have
continued. Compared with incidence estimates in 2008, AAPC
trends were similar in Asian populations that had the lowest or
insigniﬁcant AAPCs, except in Israel. China showed a stabiliza-
tion of incidence compared with an increase in 2008; this ﬁnding
suggests beneﬁcial effects of improvements in TCa diagnosis and
treatment in China. Stabilization of trends was observed in areas
where the highest incidence levels were historically observed; in
countries such as Asia and Africa, in which TCa incidence has
been historically low, incidence began to increase, with TCa
becoming an important cause of morbidity and mortality. These
ﬁndings are consistent with global cancer rates,[28] but an
Figure 3. Average annual percent change in testicular cancer (A) incidence and (B) mortality rates for the last 10 years of available data by region in all age groups.
Figure 3. Continued
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Park et al. Medicine (2018) 97:37 www.md-journal.comaccurate interpretation of the observed geographical and
temporal variations is difﬁcult, and the underlying causative
mechanisms are absent.
The introduction of cisplatin-based therapies in the late 1970s
brought about a decrease in mortality rates, with survival rates
reaching 95%. This decline in mortality rates began in Northern
andWestern Europe, the United States, and Canada in the 1970s;
these rates have now been stabilized, resulting in very low
mortality levels of approximately 0.2 per 100,000.[29] However,
signiﬁcant declines were also noted in the United States, Canada,
and most of Northern and Western Europe in 2008. Although
there have been signiﬁcant decreases in mortality in Canada, this
trend has not continued in the United States or in some Northern
and Western European countries.
Although data from GLOBOCAN, assembled from the best
sources available, have been used to quantify the incidence and
mortality rates of TCa worldwide, the quality and consistency of
these data sources may not accurately represent the international
proﬁle of TCa cases; this remains a limitation of the present study.5. Conclusion
TCa incidence rates increased in most countries examined in this
study, whereas TCa morality rates declined in most countries,
especially inmore developed countries. Absolute TCa incidence is
likely to increase, as suggested by our data. Mortality rates in
highly developed and afﬂuent countries are comparatively low
compared with other regions. The latest estimates show that TCa
survival is almost 95% in afﬂuent regions; however, of 10,351
TCa deaths, about 80% occurred in Africa, Asia, Central and
South America, and the Caribbean. This ﬁnding suggests that
prompt global actions are needed to expand and improve high-
quality diagnosis and treatment resources for cases of TCa to
reduce morbidity and mortality, speciﬁcally in more resource-
deprived countries. Future studies are needed to analyze these
epidemiological trends in association with other socioeconomic
factors as well as with TCa incidence and mortality data.
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